Moderna (MRNA:US) has released a statement today, noting that its new projections point toward substantial growth in annual sales by 2028. 

The company expects to add between $10 billion and $15 billion in annual sales following the launch of new products in the fields of oncology, rare diseases, and latent diseases. 

This optimistic outlook has had a positive impact on the company's stock, with shares opening about 8% higher on Wednesday.

The boost for new products is in addition to the announced $8 billion to $15 billion of expected sales from the respiratory franchise in 2027. Moderna previously said that it expects Covid-19 shot sales of $6 billion to $8 billion in 2023, depending on U.S. vaccination rates.

Moderna also announced that its flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial.

"Our mRNA platform is working. With today's positive Phase 3 flu results, along with previous results in COVID and RSV, we are now three for three on advancing respiratory disease programs to positive Phase 3 data," said Stéphane Bancel, Chief Executive Officer of Moderna.

“With significant momentum across the business and our pipeline, we are excited by the near future and focused on execution," Bancel added.

Congress members Ro Khanna and Daniel Goldman were trading MRNA shares this year. Most notably, Rep. Goldman sold $50,000 - $100,000 worth of MRNA shares in July this year, when they traded at around $125 apiece.

In the meantime, Moderna’s stock is trading around the $110 handle. Shares are down 41% year-to-date.